Grant: Master's Award: Canada Graduate Scholarships
University of British Columbia
$17,500.00
Engineering a novel CAR-T cell targeting the solid tumour target podocalyxin
FY 2023-24
Summary
Chimeric antigen receptor (CAR) – T cells have become one of the most promising immunotherapeutic approaches for treating cancer. Through the swapping of unique single chain fragment variable (scFv) sequences, CARs can easily be adapted to target any desired antigen, thus diversifying the types of cancer that can be treated. Although effective responses have been observed in lymphoid cancers, CARs designed to target solid tumours have shown limited efficacy for multiple reasons, among which is a lack of tumour-specific targets. To date, CAR-T cell development has focused on targeting tumour-associated proteins that become overexpressed on malignant cells. However, proteins that are overexpressed on cancerous cells but also found at lower levels throughout the body can cause on-target off-tumour toxicity. To increase CAR-T cell efficacy against solid tumours and decrease off-tumour engagement, we plan to engineer a CAR that targets a cancer-specific epitope on the protein podocalyxin (podxl). Podxl is expressed on the surface of various cell types throughout the body and is essential for development, while actively contributing to cell mobility and communication with neighbouring tissues. In the context of cancer, podxl is highly expressed on a myriad of different cancer types including breast, and testicular cancers and has been shown to enhance tumour invasiveness, promote metastasis, and is associated with poor prognosis. Recent studies have demonstrated that podxl acquires a unique glycosylation signature on tumour cells that can be targeted with an antibody, making it an ideal candidate for CARs. We aim to develop and test a novel CAR-T cell that targets the tumour-specific podxl glyco-epitope to determine specific killing and control of cancer in vitro and in vivo.
Department
Program
Master's Award: Canada Graduate Scholarships
Recipient
Location
British Columbia, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database
As published
Id
505878
Name
Bernard Grace
Region
British Columbia
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Engineering a novel CAR-T cell targeting the solid tumour target podocalyxin
Programtype2
Studentship Programs
Orgnameinp2
University of British Columbia
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Cancer; Car-T Cells; Immunotherapy; Interdisciplinary Oncology; Podocalyxin; Tumour Microenvironment
Abstract
Chimeric antigen receptor (CAR) – T cells have become one of the most promising immunotherapeutic approaches for treating cancer. Through the swapping of unique single chain fragment variable (scFv) sequences, CARs can easily be adapted to target any desired antigen, thus diversifying the types of cancer that can be treated. Although effective responses have been observed in lymphoid cancers, CARs designed to target solid tumours have shown limited efficacy for multiple reasons, among which is a lack of tumour-specific targets. To date, CAR-T cell development has focused on targeting tumour-associated proteins that become overexpressed on malignant cells. However, proteins that are overexpressed on cancerous cells but also found at lower levels throughout the body can cause on-target off-tumour toxicity. To increase CAR-T cell efficacy against solid tumours and decrease off-tumour engagement, we plan to engineer a CAR that targets a cancer-specific epitope on the protein podocalyxin (podxl). Podxl is expressed on the surface of various cell types throughout the body and is essential for development, while actively contributing to cell mobility and communication with neighbouring tissues. In the context of cancer, podxl is highly expressed on a myriad of different cancer types including breast, and testicular cancers and has been shown to enhance tumour invasiveness, promote metastasis, and is associated with poor prognosis. Recent studies have demonstrated that podxl acquires a unique glycosylation signature on tumour cells that can be targeted with an antibody, making it an ideal candidate for CARs. We aim to develop and test a novel CAR-T cell that targets the tumour-specific podxl glyco-epitope to determine specific killing and control of cancer in vitro and in vivo.
Competitiondate
202312
Approvedterm2
1 yr 0 mth
Pinamesdelim
Bernard, Grace
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~